“Benefits and risks of testosterone treatment for hypoactive sexual desire disorder in women: a critical review of studies published in the decades preceding and succeeding the advent of phosphodiesterase type 5 inhibitors” (2014) Clinics, 69(4), pp. 294–303. doi:10.1590/clin.v69i4.79512.